HEPA - Hepion Pharma NASH candidate meets phase 2 goal; up 68%
2023-05-22 07:43:13 ET
- Hepion Pharmaceuticals' ( NASDAQ: HEPA ) non-alcoholic steatohepatitis ( NASH ) candidate rencofilstat met primary and secondary endpoints in a mid-stage trial.
- The microcap is up ~68% in Monday premarket trading.
- Data from the ALTITUDE-NASH trial indicated that the drug showed improved liver function after four months of treatment in individuals with stage 3 or greater fibrosis.
- Secondary endpoints, such as reductions in the liver injury biomarkers, alanine and aspartate transaminases ("ALT" and "AST") and multiple fibrosis-associated biomarkers were also met.
- The 225 mg dose, the highest of three tested, showed the greatest benefit to liver function.
- "Our improved understanding of which subjects best respond to rencofilstat can be immediately applied to increase the likelihood of success of our larger and longer ASCEND-NASH paired biopsy trial,” Hepion ( HEPA ) CMO Todd Hobbs said in a statement .
For further details see:
Hepion Pharma NASH candidate meets phase 2 goal; up 68%